Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares

Documenti analoghi

• Efficacy and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Subgroup Analysis of Chinese Patients in the Effisayil 1 Trial
  di: Tsen-Fang Tsai, et al.
  Pubblicazione: (2023-10-01)
• Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares
  di: James G. Krueger, et al.
  Pubblicazione: (2025-09-01)
• Management of Generalized Pustular Psoriasis Flare with Intravenous Spesolimab Followed by Long-Term Treatment with Subcutaneous Spesolimab: A Case Report
  di: Angad Arinder Chadha
  Pubblicazione: (2026-04-01)
• Successful Treatment With Spesolimab in a Haemodialysis Patient With Acutely Flaring Generalised Pustular Psoriasis
  di: Yasuyuki Fujita, et al.
  Pubblicazione: (2025-12-01)
• Therapeutic Potential of Spesolimab-Sbzo in the Management of Generalized Pustular Psoriasis Flares in Adults: Evidence to Date
  di: Rega F, et al.
  Pubblicazione: (2024-03-01)